Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28413370 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL29586400 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL29626044 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL25074339 | 0.97 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066383 | 0.96 | STING1 (0.81) | STING1CYP3A4TBK1 | |
| SCHEMBL23227988 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451711 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451513 | 0.96 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066425 | 0.95 | STING1 (0.75) | STING1CYP3A4TBK1 | |
| SCHEMBL20066435 | 0.94 | STING1 (0.75) | STING1CYP3A4TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | claimed |
| CN-118215475-A | Adjuvant compositions comprising STING agonists | 葛兰素史克生物有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| WO-2023020993-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023020992-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023020994-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-4032885-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3692033-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
| WO-2019069269-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019069275-A1 | METHODS FOR ADMINISTERING STING AGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, MYD88 | STING1 1/4885CYP3A4 2253/4885TBK1 7/4885 |
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | STING1 1/4885CYP3A4 4770/4885TBK1 8/4885 |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.